Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis

被引：59

作者：

Webers, Casper ^{[1
,2
]}

Ortolan, Augusta ^{[3
,4
]}

Sepriano, Alexandre ^{[4
,5
]}

Falzon, Louise ^{[6
]}

Baraliakos, Xenofon ^{[7
]}

Landewe, Robert B. M. ^{[8
,9
]}

Ramiro, Sofia ^{[4
,9
]}

van der Heijde, Desiree ^{[4
]}

Nikiphorou, Elena ^{[4
,10
,11
]}

机构：

[1] Maastricht Univ, Dept Internal Med, Div Rheumatol, Med Ctr, Postbus 5800, NL-6202 AZ Maastricht, Netherlands

[2] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Maastricht, Netherlands

[3] Univ Padua, Dept Med DIMED, Rheumatol Unit, Padua, Italy

[4] Leiden Univ, Dept Rheumatol, Med Ctr, Leiden, Netherlands

[5] Univ Nova Lisboa, NOVA Med Sch, Lisbon, Portugal

[6] Univ Sheffield, Sch Hlth & Related Res, Hlth Econ & Decis Sci, Sheffield, S Yorkshire, England

[7] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany

[8] Univ Amsterdam, Dept Clin Immunol & Rheumatol, Med Ctr, Amsterdam, Netherlands

[9] Zuyderland Med Ctr Heerlen, Dept Rheumatol, Heerlen, Netherlands

[10] Kings Coll Hosp London, Dept Rheumatol, London, England

[11] Kings Coll London, Ctr Rheumat Dis, London, England

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷 / 01期

关键词：

spondylitis; ankylosing; biological therapy; tumour necrosis factor inhibitors; axial spondyloarthritis; ACTIVE ANKYLOSING-SPONDYLITIS; MEDIATED INFLAMMATORY DISEASES; FACTOR INHIBITOR TREATMENT; ANTI-TNF AGENTS; LONG-TERM; DOUBLE-BLIND; CERTOLIZUMAB PEGOL; OPEN-LABEL; ETANERCEPT TREATMENT; CONSENSUS STATEMENT;

D O I：

10.1136/ard-2022-223298

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective To update the evidence on efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2022 update of the Assessment of SpondyloArthritis international Society/European Alliance of Associations for Rheumatology (ASAS-EULAR) recommendations for the management of axSpA. Methods Systematic literature review (2016-2021) on efficacy and safety of bDMARDs in axSpA (radiographic axSpA (r-axSpA)/non-radiographic axSpA (nr-axSpA)). Eligible study designs included randomised controlled trials (RCTs), strategy trials and observational studies (the latter only for safety and extra-musculoskeletal manifestations). All relevant efficacy/safety outcomes were included. Results In total, 148 publications were included. Efficacy of golimumab and certolizumab was confirmed. Tumour necrosis factor inhibitor (TNFi) biosimilar-originator equivalence was demonstrated. RCT (n=15) data on efficacy of interleukin-17 inhibitors (IL-17i) demonstrated clinically relevant effects (risk ratio vs placebo to achieve ASAS40 response 1.3-15.3 (r-axSpA, n=9), 1.4-2.1 (nr-axSpA, n=2)). Efficacy of secukinumab/ixekizumab was demonstrated in TNFi-naive and TNFi-inadequate responders. IL-23 and IL-12/23 inhibitors (risankizumab/ustekinumab) failed to show relevant benefits. Tapering of TNFi by spacing was non-inferior to standard-dose treatment. The first axSpA treat-to-target trial did not meet its primary endpoint, but showed improvements in secondary outcomes. No new risks were identified with TNFi use in observational studies (data lacking for IL-17i). Secukinumab (n=1) and etanercept (n=2) were associated with increased risk of uveitis in observational studies compared to monoclonal TNFi. Conclusions New evidence supports the efficacy and safety of TNFi (originators/biosimilars) and IL-17i in r-axSpA and nr-axSpA, while IL-23i failed to show relevant effects. Observational studies are needed to confirm long-term IL-17i safety. PROSPERO registration number CRD42021257588

引用

页码：130 / 141

页数：12

共 95 条

[51] IL-23 and axial disease: do they come together? [J].

Mease, Philip ;

van den Bosch, Filip .

RHEUMATOLOGY, 2021, 60 :IV28-IV33

[52]

Merjanah S, 2020, ARTHRITIS RHEUMATOL, V72

[53] Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial [J].

Molto, Anna ;

Lopez-Medina, Clementina ;

Van den Bosch, Filip E. ;

Boonen, Annelies ;

Webers, Casper ;

Dernis, Emanuelle ;

van Gaalen, Floris A. ;

Soubrier, Martin ;

Claudepierre, Pascal ;

Baillet, Athan ;

Starmans-Kool, Mirian ;

Spoorenberg, Anneke ;

Jacques, Peggy ;

Carron, Philippe ;

Joos, Rik ;

Lenaerts, Jan ;

Gossec, Laure ;

Pouplin, Sophie ;

Ruyssen-Witrand, Adeline ;

Sparsa, Laetitia ;

van Tubergen, Astrid ;

van der Heijde, Desiree ;

Dougados, Maxime .

ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (11) :1436-1444

[54] Use of disease-modifying anti-rheumatic or anti-tumour necrosis factor drugs and risk of hospitalized infection in ankylosing spondylitis [J].

Moura, C. S. ;

Rahme, E. ;

Maksymowych, W. P. ;

Abrahamowicz, M. ;

Bessette, L. ;

Bernatsky, S. .

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2019, 48 (02) :121-127

[55] Axial spondyloarthritis [J].

Navarro-Compan, Victoria ;

Sepriano, Alexandre ;

El-Zorkany, Bassel ;

van der Heijde, Desiree .

ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (12) :1511-1521

[56] Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis [J].

Ortolan, Augusta ;

Webers, Casper ;

Sepriano, Alexandre ;

Falzon, Louise ;

Baraliakos, Xenofon ;

Landewe, Robert B. M. ;

Ramiro, Sofia ;

van der Heijde, Desiree ;

Nikiphorou, Elena .

ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (01) :142-152

[57]

Park JW, 2016, CLIN EXP RHEUMATOL, V34, P592

[58] Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study [J].

Park, Won ;

Yoo, Dae Hyun ;

Miranda, Pedro ;

Brzosko, Marek ;

Wiland, Piotr ;

Gutierrez-Urena, Sergio ;

Mikazane, Helena ;

Lee, Yeon-Ah ;

Smiyan, Svitlana ;

Lim, Mie-Jin ;

Kadinov, Vladimir ;

Abud-Mendoza, Carlos ;

Kim, HoUng ;

Lee, Sang Joon ;

Bae, YunJu ;

Kim, SuYeon ;

Braun, Juergen .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (02) :346-354

[59] A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study [J].

Park, Won ;

Hrycaj, Pawel ;

Jeka, Slawomir ;

Kovalenko, Volodymyr ;

Lysenko, Grygorii ;

Miranda, Pedro ;

Mikazane, Helena ;

Gutierrez-Urena, Sergio ;

Lim, MieJin ;

Lee, Yeon-Ah ;

Lee, Sang Joon ;

Kim, HoUng ;

Yoo, Dae Hyun ;

Braun, Juergen .

ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (10) :1605-1612

[60] Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study [J].

Pavelka, Karel ;

Kivitz, Alan J. ;

Dokoupilova, Eva ;

Blanco, Ricardo ;

Maradiaga, Marco ;

Tahir, Hasan ;

Wang, Yi ;

Porter, Brian O. ;

Stefanska, Anna ;

Richards, Hanno B. ;

Rohrer, Susanne .

ACR OPEN RHEUMATOLOGY, 2020, 2 (02) :119-127

← 1 2 3 4 5 6 7 8 9 10 →